Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration

Sponsor
Prince of Songkla University
Study ID
NCT00539734
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ranibizumab — DRUG
    A single dose of 0.5 mg ranibizumab injected intravitreally.

Study Details

Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina. Ranibizumab (Lucentis) is a new drug that inhibits the growth of new vessels and has recently been approved by FDA for treating this condition. This study is carried out to evaluate the changes in retinal function after an injection of ranibizumab.

Key Dates

First listed
Oct 4, 2007
Start date
Aug 31, 2007
Status verified
Apr 2011
Primary completion
Dec 31, 2008
Completion
Feb 28, 2009

Study Design

Enrollment
25 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Height (Amplitude) of Multifocal ERG Signal [ Time Frame: baseline, 3 months ]

Related Studies